

DO/EO BIBLIOGRAPHIC DATA ENTRY

SERIAL NUMBER:	09 / 830836	RECEIPT DATE:	05 / 01 / 01
IA NUMBER:	PCT/ EP99 / 08186	IA FILING DATE:	11 / 01 / 99
FAMILY NAME:	CAMPBELL	DELAY WAIVED (Y/N):	Y
GIVEN NAME:	IAN BAXTER	DEMAND RECEIVED (Y/N):	Y
PRIORITY CLAIMED (Y/N):	Y	PRIORITY DATE:	11 / 03 / 98
NO BASIC FEE (Y/N):	N	US DESIGNATED ONLY (Y/N):	N
ATTORNEY DOCKET NUMBER:	FG3602USM	COUNTRY:	
CORRESPONDENCE NAME/ADDRESS:	CUSTOMER NUMBER:	023347	TELEPHONE 9194832370
			FAX 9194837988
NAME:	DAVID J LEVY, VP INTELLECTUAL PROPERTY		
	GLAXO WELLCOME INC		
STREET:	GLOBAL INTELLECTUAL PROPERTY		
	FIVE MOORE DR, PO BOX 13398		
CITY:	RESEARCH TRIANGLE PARK		
STATE/COUNTRY:	NC	ZIP:	277093398
EMAIL:			
APPLICATION TITLES:	PYRAZOLOPYRIDINE DERIVATIVES AS SELECTIVE COX 2 INHIBITORS		

TAB TO LAST POSITION,PUSH SEND



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

Bib Data Sheet

CONFIRMATION NO. 3589

SERIAL NUMBER 09/830,836	FILING DATE 05/01/2001 RULE	CLASS 514	GROUP ART UNIT 1642	ATTORNEY DOCKET NO. PG3602USW
------------------------------------	---	---------------------	-------------------------------	---

APPLICANTS


Ian Baxter Campbell, Broom, GBN;
Alan Naylor, Royston, GBN;

** CONTINUING DATA *****

THIS APPLICATION IS A 371 OF PCT/EP99/08186 11/01/1999

** FOREIGN APPLICATIONS *****

UNITED KINGDOM 9824062.5 11/03/1998
UNITED KINGDOM 9920909.0 09/03/1999

Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no 35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance Verified and Acknowledged	 Examiner's Signature	Initials	STATE OR COUNTRY GBN	SHEETS DRAWING	TOTAL CLAIMS 16	INDEPENDENT CLAIMS 4
---	---	----------	--------------------------------	-----------------------	---------------------------	--------------------------------

ADDRESS

23347

TITLE

Pyrazolopyridine derivatives as selective cox-2 inhibitors

FILING FEE RECEIVED 1722	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees (Filing) <input type="checkbox"/> 1.17 Fees (Processing Ext. of time) <input type="checkbox"/> 1.18 Fees (Issue) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
------------------------------------	---	---